Close Menu

Precision Oncology Business, Policy & Funding

Breaking news on Precision Oncology business, policy & funding.

The European Commission will now consider whether to grant marketing authorization to the drug regimen.

Under the agreement, AstraZeneca will be able to use ImaginAb's CD8 ImmunoPET technology in its clinical trials in North America and Europe.

Myriad has partnered with Japanese firm SRL, a subsidiary of Miraca Group, to commercialize its BRACAnalysis Diagnostic System in Japan.

The company also plans to submit a new drug application for avapritinib in mainland China in the first half of this year. 

A drug supply agreement with Pfizer will enable Jiangsu Alphamab to study the combination of its dual-HER2 signal blocking drug, KNO26, and Ibrance.